Abstract:Dibenzo[a,c]cyclooctadiene lignans are natural products originated from Schisandra chinensis (Schisandraceae), a well-known medicinal plant in traditional Chinese medicine. The fruits and seeds have been used for centuries as a tonic and antitussive. Many studies have indicated that the active ingredients are lignans possessing an unusual structure derived from dibenzo[a,c]cyclooctadiene These lignans have been shown to possess a broad range of biological effects, including hepatoprotective and antiviral properties. Recently, dibenzocyclooctadiene lignans have been discussed as compounds that are able to overcome multidrug resistance. A panel of nine dibenzo[a,c]cyclooctadiene lignans (schizandrin, gomisin A, gomisin N, gomisin J, angeloylgomisin H, tigloylgomisin P, deoxyschizandrin, gammaschizandrin and wuweizisu C), isolated by us from seeds of S. chinensis, was examined for their effect on multidrug resistance, as well as their anti-proliferative and pro-apoptotic activities. CORL23/R, a multidrug resistant subline overexpressing multidrug resistanceassociated protein 1 (MRP1) together with its parent cell line CORL23 (human lung cell carcinoma) and HL60 (human promyelocytic leukemia) cell lines were used. We found that deoxyschizandrin and gammaschizandrin at relatively nontoxic concentrations restored the cytotoxic action of doxorubicin, a MRP1 substrate, to CORL23/R cells. Moreover, deoxyschizandrin and gammaschizandrin showed the greatest ability to enhance the accumulation of doxorubicin in drug resistant cells. Lignans alone had no effect on the cell cycle, however, in combination with subtoxic doses of doxorubicin, cell were arrested in the G2/M phase, which is typical for doxorubicin at toxic doses. Our results suggest that deoxyschizandrin and gammaschizandrin potentiate the effect of doxorubicin in doxorubicin resistant lung cancer cells by increasing the accumulation of doxorubicin inside the cells. The common structural feature of both active lignans and missing from the less active or inactive lignans is the Rbiaryl configuration and the absence of a hydroxy group at C8. Unlike the reversion effect, the cytotoxicity of lignans with either the Rbiaryl or Sbiaryl configurations was approximately same.

Schisandrin A Enhances the Cytotoxicity of Doxorubicin by the Inhibition of Nuclear Factor-Kappa B Signaling in a Doxorubicin-Resistant Human Osteosarcoma Cell Line

Schisandrin B inhibits cell proliferation and induces apoptosis in human cholangiocarcinoma cells.

Mechanism Study of Doxorubicin-schisandrin B Co-delivery Liposomes to Overcome Multidrug Resistance

Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation

Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells.

Schisandrin B enhances doxorubicin-induced apoptosis in SMMC7721 cell line

Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo

Schisandrin A can promote the anti-tumor effect of 5-Fu by reversing the immunosuppressive state of the body in rat

Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.

Schisandrin B Inhibits Osteosarcoma Cell Proliferation and Promotes Apoptosis Through PI3K/AKT/mTOR Pathway Mediated Autophagy

Schisandrin B Ameliorated Chondrocytes Inflammation and Osteoarthritis Via Suppression of NF-κB and MAPK Signal Pathways.

Enhanced Chemosensitivity by Simultaneously Inhibiting Cell Cycle Progression and Promoting Apoptosis of Drug-Resistant Osteosarcoma Mg63/Dxr Cells by Targeting Cyclin D1 and Bcl-2

Schizandrin B Inhibits the Cis‑ddp‑induced Apoptosis of HK‑2 Cells by Activating ERK/NF‑κB Signaling to Regulate the Expression of Survivin.

Lignans from Schisandra chinensis restore the cytotoxic action of doxorubicin in drug resistant lung cancer cells

Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small cell lung cancer

Schisandrin B--a novel inhibitor of P-glycoprotein.

Reversal of Resistance to Doxorubicin by CJZ3, a Lomerizine Amlodipine Derivative,in Doxorubicin-Resistant Human Myelogenous Leukemia(k562/dox) Cells

A New Chalcone Derivative C49 Reverses Doxorubicin Resistance in MCF-7/DOX Cells by Inhibiting P-Glycoprotein Expression

Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway

A nanomicelle with miR-34a and doxorubicin reverses the drug resistance of cisplatin in esophageal carcinoma cells by inhibiting SIRT1 signal pathway

Co-Delivery of Doxorubicin and Schisandrin B by Liposome to Overcome Multidrug Resistance